2.52 USD
-0.17
6.32%
At close Apr 1, 3:59 PM EDT
After hours
2.54
+0.02
0.79%
1 day
-6.32%
5 days
-13.40%
1 month
-8.03%
3 months
-49.60%
6 months
-17.11%
Year to date
-49.60%
1 year
-27.79%
5 years
-76.11%
10 years
-44.25%
 

About: Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Employees: 188

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

87% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 30

58% more capital invested

Capital invested by funds: $194M [Q3] → $306M (+$112M) [Q4]

15% more funds holding

Funds holding: 116 [Q3] → 133 (+17) [Q4]

9.95% less ownership

Funds ownership: 88.75% [Q3] → 78.81% (-9.95%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for CDXS.

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.
Codexis Announces New Employment Inducement Grants
Neutral
Seeking Alpha
1 month ago
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Georgia Erbez - Chief Financial Officer Conference Call Participants Richard Miller - Cantor Fitzgerald, L.P. Matthew Stanton - Jefferies Group LLC Allison Bratzel - Piper Sandler Companies Dan Arias - Stifel Financial Corp. Jacob Johnson - Stephens Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC Brendan Smith - TD Cowen Operator Welcome to the Codexis Fourth Quarter and Full Year 2024 Earnings Conference Call.
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.02 per share a year ago.
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 39,000 shares of Codexis common stock and (ii) 27,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.
Codexis Announces New Employment Inducement Grants
Neutral
GlobeNewsWire
1 month ago
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
Neutral
GlobeNewsWire
1 month ago
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform.
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board
Neutral
GlobeNewsWire
2 months ago
Codexis Appoints Christos Richards to Board of Directors
REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors.
Codexis Appoints Christos Richards to Board of Directors
Neutral
GlobeNewsWire
2 months ago
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 23,000 shares of Codexis common stock and (ii) 11,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.
Codexis Announces New Employment Inducement Grants
Neutral
GlobeNewsWire
3 months ago
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 168,400 shares of Codexis common stock and (ii) 39,750 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan.
Codexis Announces New Employment Inducement Grants
Neutral
GlobeNewsWire
4 months ago
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
Charts implemented using Lightweight Charts™